EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma

Ruonan Zhang, Jie Wang, Yu Du, Ze Yu, Yihan Wang, Yixiao Jiang, Yixin Wu, Ting Le, Ziqi Li, Guoqiang Zhang, Lei Lv iD, Haijie Ma

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-007529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Ruonan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the past few years, immunotherapies of hepatocellular carcinoma (HCC) targeting programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1), have achieved durable clinical benefits. However, only a fraction of HCC patients showed objective clinical response to PD-1/PD-L1 blockade alone. Despite the impact on post-translational modifications of PD-L1 being substantial, its significance in resistance to HCC immunotherapy remains poorly defined.

Methods

Cyclin-dependent kinase 5 (CDK5) expression was knocked down in HCC cells, CDK5 and PD-L1 protein levels were examined by Western blot. Coimmunoprecipitation was conducted to evaluate the interaction between proteins. Preclinical HCC mice model was constructed to evaluate the effect of CDK5 inhibitor alone or in combination with PD-1 antibody. Clinical HCC samples were used to elucidate the clinical relevance of CDK5, PD-L1, and PD-L1 T290 phosphorylation in HCC.

Results

We find that CDK5 deficiency upregulates PD-L1 protein expression in HCC cells and decipher a novel molecular mechanism under which PD-L1 is downregulated by CDK5, that is, CDK5 mediated PD-L1 phosphorylation at T290 promotes its binding with chaperon protein heat-shock cognate protein 70 (HSC70) and degradation through chaperon-mediated autophagy. Notably, treatment of CDK5 inhibitor, PNU112455A, effectively upregulates the tumorous PD-L1 level, promotes the response to anti-PD-1 immunotherapy,and prolongs the survival time of mice bearing HCC tumors. What is more, the T290 phosphorylation status of PD-L1 correlates with the prognosis of HCC.

Conclusions

Targeting CDK5 can synergize with PD-1 blockade to suppress HCC growth, which may have clinical benefits. Our study reveals a unique regulation of the degradation of PD-L1 in HCC, and provides an attractive therapeutic target, a potential drug, and a new prognostic marker for the clinical treatment of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsHumansMiceAutophagyB7-H1 AntigenCyclin-Dependent Kinase 5LigandsProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyTumor Biomarkers

Substanzen

B7-H1 AntigenCyclin-Dependent Kinase 5LigandsProgrammed Cell Death 1 ReceptorCd274 protein, mouseCdk5 protein, mouse

Autor:innen und Institutionen

  • Cellular and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang, China.
  • MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Nourse Centre for Pet Nutrition, Wuhu, Anhui, China.
  • School of Management, Xi'an Jiaotong University, Xi'an, Shanxi, China.
  • Department of General Surgery, Zhoushan Hospital, Zhoushan, Zhejiang, China.
  • MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China haijie215@163.com lvlei@fudan.edu.cn.

ORCID-Profile: Lei Lv

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, R., Wang, J., Du, Y., Yu, Z., Wang, Y., Jiang, Y., Wu, Y., Le, T., Li, Z., Zhang, G., Lv, L., & Ma, H. (2023). CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007529

Vancouver

Zhang R, Wang J, Du Y, Yu Z, Wang Y, Jiang Y, et al. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007529

BibTeX
@article{Zhang2023,
  author = {Zhang, Ruonan and Wang, Jie and Du, Yu and Yu, Ze and Wang, Yihan and Jiang, Yixiao and Wu, Yixin and Le, Ting and Li, Ziqi and Zhang, Guoqiang and Lv, Lei and Ma, Haijie},
  title = {CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-007529}
}
Kostenlos starten →